00474.HK
Aceso Life Science Group Limited
HKSE · Industrials · Conglomerates · HK
HKD 0.15
−0.66%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 183.0M | 195.0M | 11.0M | 312.0M | 315.0M |
| Cost of Revenue | 290.0M | 105.0M | 111.0M | 171.0M | 153.0M |
| Gross Profit | (64.0M) | 90.0M | (100.0M) | 141.0M | 162.0M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 177.0M | 114.0M | 124.0M | 123.0M | 146.0M |
| General & Admin Expense | 178.0M | 114.0M | 124.0M | 123.0M | 146.0M |
| Selling & Marketing Expense | (1.0M) | — | — | — | — |
| Other Expenses | 114.0M | — | (7.0M) | 69.0M | 35.0M |
| Total Operating Expenses | 704.0M | 114.0M | 117.0M | 125.0M | 152.0M |
| Cost and Expenses | 809.0M | 219.0M | 228.0M | 296.0M | 305.0M |
| Operating Income (EBIT) | (209.0M) | (24.0M) | (224.0M) | (153.0M) | 10.0M |
| Non-Operating | |||||
| Interest Income | 5.0M | 10.0M | 35.0M | 30.0M | 21.0M |
| Interest Expense | 41.0M | 124.0M | 143.0M | 140.0M | 154.0M |
| Net Interest Income | (36.0M) | (114.0M) | (108.0M) | (110.0M) | (133.0M) |
| Other Non-Op Income/Expense | (904.0M) | (1.0B) | (599.0M) | (123.0M) | (419.0M) |
| Non-Operating Income (excl Interest) | 475.0M | 879.0M | 456.0M | (17.0M) | 265.0M |
| EBT (Pre-Tax Income) | (1.1B) | (1.0B) | (823.0M) | (213.0M) | (555.0M) |
| Income Tax Expense | (14.0M) | (10.0M) | (14.0M) | (5.0M) | 41.0M |
| Bottom Line | |||||
| Net Income | (764.0M) | (895.0M) | (462.0M) | (264.0M) | (370.0M) |
| Earnings from Cont. Ops | (1.1B) | (1.0B) | (809.0M) | 1.0M | (596.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (1.0B) | (895.0M) | (462.0M) | (264.0M) | (413.0M) |
| Per Share | |||||
| Basic EPS | (HK$0.15) | (HK$0.12) | (HK$0.06) | (HK$0.04) | (HK$0.05) |
| Diluted EPS | (HK$0.15) | (HK$0.12) | (HK$0.06) | (HK$0.04) | (HK$0.05) |
| Revenue Per Share | HK$0.02 | HK$0.03 | HK$0.00 | HK$0.04 | HK$0.04 |
| Shares | |||||
| Basic Shares Outstanding | 7.3B | 7.2B | 7.3B | 7.3B | 7.2B |
| Diluted Shares Outstanding | 7.3B | 7.2B | 7.3B | 7.3B | 7.4B |
| Profitability Metrics | |||||
| EBITDA | (320.0M) | (860.0M) | (220.0M) | (21.0M) | (359.0M) |
| D&A | 188.0M | 43.0M | 50.0M | 52.0M | 68.0M |
| EBIT | (466.0M) | (903.0M) | (680.0M) | (73.0M) | (401.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2025